Key Highlights

  • Shares rose 0.51% to USD 15.86 on relative Volume of 1.96.
  • Third-quarter net loss was USD 128 million, or USD 1.00 per share.
  • October stock sale raised gross proceeds of about USD 288 million.
  • Management will present at investor conferences on December 1 and 2, 2026.

Arcus Biosciences (NYSE:RCUS) shares traded at USD 15.86 on November 20, 2026, up 0.51%, with a relative volume at time of 1.96. The company has given no reason for the heavy trading. On record are its report for the quarter ended September 30, 2026, filed on November 4, an October underwritten public offering and an announcement that management will present at two investor conferences in December.

Arcus is a Delaware corporation based in Hayward, California. It is a late clinical-stage biopharmaceutical company developing molecules for cancer and immunology diseases, drawing on its internal small-molecule discovery capabilities. It operates as one segment, has no product sales Revenue and has recognized revenue through collaboration and license arrangements with partners including Gilead and Taiho. Its fiscal year ends on December 31.

December Conference Plans

Management will present at the Evercore and Citi conferences, scheduled for December 1 and 2, 2026.

Third-Quarter Results

Total revenues were USD 9 million versus USD 26 million a year earlier. License and development services revenue was USD 8 million versus USD 20 million, and other collaboration revenue was USD 1 million versus USD 6 million. Research and Development expenses were USD 117 million versus USD 141 million, and general and administrative expenses were USD 23 million versus USD 27 million.

The loss from operations was USD 131 million versus USD 142 million. The net loss was USD 128 million, or USD 1.00 per share, against USD 135 million, or USD 1.27.

For nine months, total revenues were USD 67 million versus USD 214 million. Research and development expenses were USD 352 million versus USD 402 million, and general and administrative expenses were USD 76 million versus USD 84 million. The operating loss was USD 361 million versus USD 272 million, and the net loss was USD 347 million, or USD 2.74 per share, versus USD 247 million, or USD 2.39.

Cash, Debt and the October Offering

Cash and cash equivalents were USD 151 million versus USD 222 million at year end, and marketable securities were USD 479 million versus USD 759 million. Total Assets were USD 818 million versus USD 1,139 million, and long-term debt was USD 102 million versus USD 99 million. Operating Activities used USD 345 million versus USD 362 million.

In October, Arcus sold 16.4 million shares at USD 17.50 each in an underwritten public offering, for gross proceeds of about USD 288 million before Underwriting discounts, commissions and expenses. The company expects its USD 694 million of cash, cash equivalents and marketable securities at September 30, plus the offering proceeds, to fund planned operations into 2029. It will need additional funding to continue operations and pursue its development strategy.

Casdatifan and Partnership Updates

In October, Arcus announced new ARC-20 platform data for casdatifan in clear cell renal cell carcinoma. With zimberelimab in first-line treatment (30 patients), the confirmed response rate was 50%, and landmark progression-free survival was 86% at six months and 69% at 12 months. With cabozantinib in the second line (43 patients), median progression-free survival was 14.5 months and the confirmed response rate was 44%. As monotherapy in late-line treatment (121 patients), median overall survival was 35 months, median progression-free survival was 13 months and the confirmed response rate was 36%.

Gilead's option rights ended on July 14, 2026, after Gilead decided against making the option continuation payment. In August, Arcus discontinued the Phase 3 PACIFIC-8 study of domvanalimab and later signed a termination agreement with AstraZeneca.

What to Watch Next for Arcus Biosciences

The company has given no reason for the November 20 volume, and its results, offering and conference plans came earlier. The reported record shows lower revenue, a smaller quarterly loss, lower cash before the offering and a runway into 2029. The December presentations and further casdatifan data are the points to follow.